New drug applications approved by US FDA as of 1 - 15 Feb 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Researchers conducted a retrospective review of electronic medical records for all MKTPs performed at Henry Ford Hospital between January 2009 and April 2014 to assess long-term repigmentation of MKTP in vitiligo and other leukodermas. A 5-point grading scale (poor to excellent) and Vitiligo Area Scoring Index (VASI) were utilized to evaluate repigmentation.

MKTP was performed at 236 anatomically based lesions (ABLs) in a total of 100 patients, of which 63 with 157 ABLs had available long-term data (12 to 72 months; median 24 months).

Age, skin photoype and anatomic location of ABLs did not show any significant impact on the outcome of treatment.

These results support a previous study, which found MKTP to be effective and well-tolerated based upon categorical and VASI assessments of repigmentation. [J Am Acad Dermatol 2012;66:785-93]

The current study is limited by the retrospective design with uncontrolled, postoperative adjuvant treatments and inconsistent compliance to scheduled follow-up evaluations, according to researchers, adding that persistence of pigmentation after MKTP is a critical consideration for efficacy.

New drug applications approved by US FDA as of 1 - 15 Feb 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.